Join
Live feed
·
PRReleasevia Quantisnow
Seres Therapeutics Inc. logo

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

ByQuantisnow·Wall Street's wire, on your screen.
MCRB· Seres Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MCRB (Seres Therapeutics Inc.) and more on Quantisnow.